Riin Reimets Selected Research

Riin Reimets Research Topics

7	Wolfram Syndrome (Syndrome, Wolfram) 01/2023 - 08/2015
3	Glucose Intolerance 01/2023 - 03/2019
3	Hypoxia (Hypoxemia) 01/2018 - 07/2012
2	Disease Progression 01/2023 - 11/2021
2	Atrophy 01/2021 - 01/2017
2	Hypothermia 01/2018 - 04/2014
1	Sensorineural Hearing Loss 11/2021
1	Cognitive Dysfunction 01/2021
1	Inflammation (Inflammations) 01/2021
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2021
1	Neuroinflammatory Diseases 10/2019
1	Diabetes Mellitus 10/2019
1	Hyperglycemia 03/2019
1	Gliosis 01/2017
1	Mood Disorders (Mood Disorder) 01/2016
1	Mental Disorders (Mental Disorder) 01/2015
1	Ischemia 07/2012
1	Infarction (Infarctions) 07/2012
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 07/2012
1	Stroke (Strokes) 07/2012

3	Liraglutide FDA Link 11/2021 - 10/2019
2	Insulin (Novolin)FDA Link 03/2019 - 01/2017
2	AntioxidantsIBA 01/2018 - 04/2014
1	Therapeutic UsesIBA 01/2023
1	IncretinsIBA 01/2023
1	SolutionsIBA 11/2021
1	6,7-dihydroxyflavoneIBA 01/2021
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2021
1	Glucagon-Like Peptide-1 ReceptorIBA 10/2019
1	Neuroprotective AgentsIBA 10/2019
1	Glucose (Dextrose)FDA LinkGeneric 03/2019
1	Transcription Factors (Transcription Factor)IBA 01/2018
1	Retinaldehyde (Retinal)IBA 01/2017
1	Antidepressive Agents (Antidepressants)IBA 01/2016
1	Ethanol (Ethyl Alcohol)IBA 08/2015
1	limbic system-associated membrane proteinIBA 01/2015
1	RNA (Ribonucleic Acid)IBA 04/2014
1	Reactive Oxygen Species (Oxygen Radicals)IBA 07/2012
1	CytoglobinIBA 07/2012
1	salicylhydroxamic acid (SHAM)IBA 07/2012

1	Therapeutics 01/2023
1	Induced Hypothermia 01/2018